

## A Randomised Trial of a Wearable UV dosimeter for Skin Cancer Prevention

George I Varghese, M.D.<sup>1</sup>, Peter D Kaplan, Ph.D.<sup>2</sup>, Catherine Do, M.D., Ph.D.,<sup>3</sup> Melissa Barrer, M.M.S.,<sup>1</sup> Khaled Ezzedine, M.D., Ph.D.,<sup>4</sup> Jonathan H Zippin, M.D., Ph.D.,<sup>1</sup> Emmanuel LP Dumont, Ph.D.<sup>2, 5</sup>

<sup>1</sup> Department of Dermatology, Weill Cornell Medicine, New York, New York

<sup>2</sup> Shade, 111 Ideation Way, Nutley, NJ

<sup>3</sup> Department of Pathology, New York University Langone Health, 22nd Floor, 240 East 38th Street, New York, NY 10016

<sup>4</sup> University Hospital Henri Mondor, Department of Dermatology, 51 Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France

<sup>5</sup> Hackensack Meridian Center for Discovery and Innovation, 111 Ideation Way, Nutley, NJ

### Corresponding author:

Emmanuel Dumont

111 Ideation Way, Nutley, NJ, 07110

em@shade.io

**Funding sources:** National Cancer Institute, contract HHSN261201700005C.

**Conflicts of Interest:** Emmanuel Dumont and Peter Kaplan are employees of Shade. Emmanuel Dumont, Peter Kaplan, Jonathan Zippin are shareholders of Shade.

**IRB.** This trial was approved by the IRB of Weill-Cornell Medicine.

**Keywords:** actinic keratosis; basal cell carcinoma; cancer biology; clinical trials; controlled trials; photoprotection; photosensitivity; squamous cell carcinoma

## ABSTRACT

---

### Background

Non-melanoma skin cancer (NMSC) is the most prevalent cancer in the United States. Despite guidelines on UV radiation avoidance, it remains difficult for people to assess their individual exposure, as UV is invisible and the onset of UV-induced symptoms is delayed.

### Objective

To measure the clinical impact of a wearable UV dosimeter that provides real-time information to users.

### Methods

In a prospective randomised trial, ninety-seven elderly patients with a history of actinic keratoses (AK) were enrolled and followed over six months. Fifty patients were given a wearable UV dosimeter that provided real-time and cumulative daily UV exposure, and forty-seven patients received UV protection counseling by a dermatologist.

### Results

After 6 months of intervention, when comparing the device group to the control group, we observed a 20% lower ratio of incidence rates of AKs (95% CI = [-41%, 55%], p-value = 0.44) and a 95% lower ratio of incidence rates of NMSCs (95% CI = [33%, 99.6%], p-value = 0.024).

### Limitations

The study has a short duration and a small sample size.

### Conclusion

This pilot clinical trial suggests that providing real-time UV exposure data using a wearable UV dosimeter may assist in the reduction of NMSC in an elderly population.

## INTRODUCTION

---

Skin cancer is the most common cancer in the United States.<sup>1</sup> Genetic, phenotypic, and environmental factors, specifically ultraviolet radiation (UVR), are considered the largest contributing factors to the development of skin cancer.<sup>2</sup> Recent controversies on the effectiveness<sup>3</sup> and safety<sup>4</sup> of sunscreens have created a critical need for safer strategies to help manage UVR exposure. UVR dosimeters provide a data-driven solution for assessing and communicating the real-time risk of UVR. In this prospective, randomised clinical trial, we assessed the clinical efficacy of the Shade UV dosimeter and mobile app in an elderly patient population with a history of actinic keratoses.

## METHODS

---

### Study design

This prospective, randomised, observer-blinded, controlled clinical trial enrolled elderly patients with a history of actinic keratoses at a single site in New York City, NY. The trial was conducted under the oversight of the Institutional Review Board (IRB) of Weill Cornell Medicine and the National Cancer Institute (NCI) of the National Institutes of Health. It adhered to applicable governmental regulations. The IRB and the NCI approved the protocol and the consent forms. All participants provided written informed consent before enrollment. The sponsor, YouV Labs, Inc., and the PI of the trial (GV) were responsible for the overall trial design, site selection, monitoring, and data analysis. Investigators were responsible for data collection, recruitment, and treatment. The authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol. The trial was registered on [clinicaltrials.gov](https://clinicaltrials.gov) under the identification NCT03315286.


### Participants, randomization, and data blinding

Eligible participants were 18 years of age or older with a history of actinic keratosis (AKs, one diagnosis in the 12 months prior to enrollment or 5 AKs in the five years prior to enrollment). Patients having received UV therapy in the past six months or field therapy for the treatment of actinic keratosis in the past three months were excluded. Participants were assigned using randomly-generated blocks of four, stratified by skin type, to receive a wearable UV dosimeter and standard-of-care UVR education or solely standard-of-care UVR education. The randomization in blocks of four was used to balance seasonal trends in UV exposure. All participants received \$50 USD per visit (up to \$150 USD across the study) and participants receiving a dosimeter were encouraged to wear it every day and received a compliance payment of \$20 USD per visit if they used it at least two days per week (up to \$40 USD across the study). At enrollment, all participants from both groups were advised to minimize their UV exposure using sunscreen and protective clothing. Participants were enrolled from April to July 2018 and had two follow-up visits at 3-month intervals. The final visits ran from November to January 2019. All participants from both groups were examined by the same dermatologist who was blinded to their group assignment.

### Wearable UV dosimeters

The sponsor provided the Shade UV dosimeters and a companion smartphone application. The dosimeters were designed to measure the UV index (UVI), a real-time measure of the strength of

UVR relevant to skin health. Its accuracy was evaluated across New York and Florida in various sunlight situations.<sup>5</sup> The dosimeters measured the UVI every second and aggregated the cumulative dose every 6 minutes. They were designed to be worn on the chest using a magnetic attachment (See Figure 1). The sponsor developed an application for both Apple and Android smartphones that connected to the UV dosimeter via Bluetooth. While connected to a Shade UV dosimeter, the smartphone application displayed a real-time UV index, real-time cumulative UV exposure, as well as historical data of daily UV exposure. At enrollment, participants receiving the dosimeter were trained to use the dosimeter and select a daily UV dose threshold on the application. This threshold was customizable through the application and was used to send real-time alerts. Participants could also input their sunscreen use into the application, and the cumulative UV exposure would be divided by the sun protection factor (SPF) during the two hours following sunscreen application.



**Figure 1.** Wearable UV dosimeter, its magnet, and its companion smartphone application.

### **Safety assessments**

Safety assessments included monitoring of adverse events related or possibly related to the device or sun exposure experienced within the study period. Adverse events were to be reported to the clinical principal investigator, the study coordinator, the IRB, and the NCI.

### **Efficacy assessments**

A single, blinded dermatologist counted AK lesions and NMSC on sun-exposed skin areas (scalp, face, hands) at enrollment and at each subsequent visit (three months after enrollment and six months after enrollment). Pictures of every lesion and its locations were recorded. AKs are defined as keratotic macule(s) or papule(s) on an erythematous base. To ensure that only new AKs or NMSCs after enrollment were counted, each lesion's location and picture were compared to prior lesions (AK or NMSC). The primary endpoint was the incidence rate of AKs at disenrollment compared to the intermediary visit. Secondary clinical endpoints included the incidence rate of non-melanoma skin cancers (squamous cell carcinoma (SCC) and basal cell carcinoma (BCC)

combined). All AKs were treated at the time of visit with cryotherapy, a modality known to eliminate these precancerous lesions. Furthermore, eliminating all visible AKs was required to accurately follow the longitudinal AK incidence. All lesions suspected of being cancerous were biopsied and the diagnoses confirmed by a blinded pathologist at Weill Cornell Medicine. Other secondary endpoints included scores on surveys of anxiety, depression, and the ability to participate in social activities. Surveys were 8-question forms from the National Institute of Health's Patient-Reported Outcomes Measurement Information System (PROMIS).

### **Data entry**

Case Report Forms (CRFs) were filled out by participants, the study coordinator, and the dermatologist on paper. CRF's were monitored for completeness, consistency, and agreement with underlying medical records periodically during the study. CRFs were scanned and data entered by two people. Discrepancies between the two entries were reconciled manually.

### **Statistical analysis**

Incidence rates (IR) of AK and NMSC within 3-month intervals at the intermediary visit and disenrollment were calculated using Poisson models. The incidence rate ratio (IRR) between groups was calculated using a longitudinal approach comparing the changes in IRs between the intermediary visit and disenrollment in each group. Statistically, the IRR is the slope estimated by the interaction term between time and group assignment in the Poisson model. As our data is censored on the left (the lesions observed at enrollment occurred during an undetermined time interval), the change in IRs was only calculated between the intermediary visit and disenrollment. The IR at the intermediary visit is the reference IR. To control for confounding factors, we used a multivariate Poisson model including any clinico-demographic variables with a significant or sub-significant difference between groups at baseline ( $p$ -value $<0.1$ ). In our trial, we controlled for age and gender (see Table 1). Categorical variables were tested using the Chi-squared test or the Fisher's exact test, and continuous variables using Welch t-tests or non-parametric Spearman tests. Normality was tested using skewness and kurtosis tests. All  $p$ -values were computed using two-tailed tests and performed using STATA® v13 (STATA corp).

## **RESULTS**

---


### **Trial population**

Between April 1, 2018, and July 31, 2018, a total of ninety-seven patients underwent randomization. Fifty were assigned to the device group and received a Shade UV sensor and UV protection counseling, and forty-seven were assigned to the control group and received UV protection counseling only (Figure 2). Following enrollment, one patient in the device group was excluded from the per-protocol population for missing a protocol visit, and four patients in the control group were excluded from the per-protocol population for either lack of compliance with treatment protocol (1) or for missing protocol visits (3). Skin type, defined by the Fitzpatrick scale (from 1 to 6),<sup>6</sup> were balanced between the device and the control group (Table 1). Participants with a Fitzpatrick skin type 1 or 2 accounted for 92% of the participants, and the remaining 8% had a Fitzpatrick skin phototype 3. Gender, skin type, ethnicity, race, education, and known skin cancer risk factors were balanced in the two groups (cf. Table 1). All participants reported their race to be

White. The mean age of the participants was 66 years. Despite randomization, the participants in the device group were significantly younger than the participants in the control group by five years on average. The imbalance in age was accounted for in the statistical analysis.

### Safety

No adverse events were reported during the trial.




**Figure 2. Randomization and Analysis Populations.**

### Efficacy

In Figure 3, we present the incidence rates (AK and NMSC) at the intermediary visit (3 months after enrollment), and disenrollment (after summer, six months after enrollment). The IRR was calculated using a Poisson regression analysis after controlling for gender and age. Six months in the intervention, we measured an IRR of 0.799 (p-value = 0.44, 95% CI: 0.450 - 1.415) for AKs and an IRR of 0.05 (p-value = 0.024, 95% CI: 0.004 - 0.67) for NMSC.

The NIH's PROMIS questionnaires have 8 questions each rated from 1 to 5, for a combined raw total score between 8 and 40. We assessed depression, anxiety, and the ability to participate in social events. The raw scores are processed by the PROMIS tool (healthmeasures.net) to provide t-scores. We found a relative decrease of 2.1 points (p-value = 0.010, 95% CI: -3.69, -0.50) in self-reported ability to participate in social events in the device group compared to the control group.

In Figure 4, we present the adherence of UV behavior of participants in the device group. We found that 75% of participants registered UV exposure at least once a week over the summer. In Figure 5, we present the distribution of the mean daily UV exposure over August and September as a function of the number of AKs measured at disenrollment among patients in the device group. Using Welch's 2-sample t-test, we found that the group with a low number of AKs had a mean UV exposure of 0.33 SED, and the group with a high number of AKs had a mean UV exposure of 0.60 SED (p-value = 0.0354).



**Figure 3.** Incidence rate of new AK and NMSC at 3 and 6 months in the intervention. The incidence rate ratio (the ratio of the changes in incidence rates in the two groups), relative differences (1 - IRR, multiplied by 100), and p-values are estimated from a Poisson model that includes gender and age as covariates. When the covariates gender and age were omitted, the conclusions remained unchanged. The ratio of incidence rates of NMSCs at 6 months was significantly lower in the device group than in the control group (relative difference: 95.0%, p-value = 0.024). This benefit with the device was also observed for AKs but not significantly (relative difference: 20.1%, p-value = 0.44).

## DISCUSSION

This pilot randomised clinical trial was designed to evaluate a novel sun protection strategy where real-time, accurate UV information is provided to elderly participants without specific recommendations on UV dose limits. Our study was powered to detect a 25% reduction in the rate of newly-formed AKs over one summer. AKs are an ideal outcome measure in a study evaluating the efficacy of a sun protection tool because they are seasonal, and therefore triggered by UV exposure, are predictive of SCC incidence, and are 10-20x more prevalent than NMSC.<sup>7</sup> After six months of intervention, we observed a 20% lower ratio of incidence rates (CI = [-41%, 55%], p-value = 0.44) in the device group compared to the control group. Amongst the reasons for failing to observe a statistically significant reduction are random variations (the study power was 80%), and a smaller real effect than the 25% that the study was powered to detect.

<b>Table 1. Demographic and clinical characteristics.</b>				
<b>Characteristics</b>	<b>Control (N = 43)</b>	<b>Device (N = 49)</b>	<b>Total (N = 92)</b>	<b>P-value</b>
Gender - no. of participants (%)				0.119
Male	24 (56%)	35 (71%)	59 (64%)	
Female	19 (44%)	14 (29%)	33 (36%)	
Mean age (SD) - yr	69 (7.0)	64 (10)	66 (9)	0.0001 (*)
Diagnosed with NMSC at enrollment - no. of participants (%)				0.49
No	39 (91%)	41 (84%)	80 (87%)	
Yes	4 (9%)	8 (16%)	12 (13%)	
Race - no. of participants (%)				n/a
White	43 (100%)	49 (100%)	92 (100%)	
Not White	0 (0%)	0 (0%)	0 (0%)	
Ethnicity - no. of participants (%)				0.494
Hispanic or Latino	0 (0%)	2 (4%)	2 (2%)	
Not Hispanic or Latino	38 (88%)	39 (80%)	77 (84%)	
Unknown	5 (12%)	8 (16%)	13 (14%)	
Fitzpatrick type - no. of participants (%)				0.429
Type 1	11 (26%)	19 (39%)	30 (33%)	
Type 2	27 (63%)	26 (53%)	53 (58%)	
Type 3	5 (12%)	4 (8%)	9 (8%)	
Education - no. of participants (%)				0.931
Did not complete college	5 (12%)	6 (12%)	11 (12%)	
Completed college	37 (86%)	42 (86%)	79 (86%)	
Unknown	1 (2%)	1 (2%)	2 (2%)	
Risk factor for skin cancer - no. of participants (%)				
Had phototherapy in the 6 months prior to enrollment	0 (0%)	1 (2%)	1 (1%)	1.000
Current smoker	1 (2%)	1 (2%)	2 (2%)	1.000
Regular user of a tanning bed	1 (2%)	0 (0%)	1 (1%)	0.467


SD = Standard Deviation. All demographic characteristics were reported by the participant except for the Fitzpatrick skin type, reported by the clinical principal investigator. For categorical covariates, p-values were calculated using Chi-square tests (gender and education) and Fisher's exact tests when the Chi-squared test requirement was not met (ethnicity, smoking status, skin type, use of a tanning bed, and history of phototherapy). We used a Spearman t-test for the age.



Additionally, after six months, we measured a statistically significant 95% lower ratio of incidence rates of NMSCs (p-value = 0.024, 95% CI: [33%, 99.6%]). An improvement of the NMSC incidence rate over 6 months seems surprising at first sight. However, our trial population is elderly (its median age is 66 years old) and at high risk of skin cancer. Also, short-term effects on NMSC incidence rates are not unprecedented. In 2015, Chen et al. demonstrated through a randomised clinical trial that nicotinamide significantly reduces the incidence rate of NMSC in 12 months in an elderly population.<sup>8</sup> Chen's and our trial suggest that the late stages of NMSC pathogenesis may be impacted by more recent events and therefore be slowed through intervention, similar to smoking cessation which reduces the relative risk of lung cancer after one year.<sup>9</sup> Finally, our result is consistent with two established molecular mechanisms and a murine model. The first one is related to the biology of p53 immunopositive epidermal keratinocytes (p53 "patches"). These p53 patches follow UVR exposure<sup>10</sup> and are associated with carcinoma of the skin, with 50% of all skin cancers expressing these mutations.<sup>11,12</sup> The prevalence of p53 patches increases with age until saturation, when people reach the age of 60 years old.<sup>13</sup> Using a murine model, Rebel et al. showed that SCCs start appearing immediately after p53 patch saturation, and their count grows exponentially with time when mice continue to be exposed to daily UVR.<sup>14</sup> These data suggest that short-term UV exposure may trigger the appearance of NMSCs after the skin is saturated with p53 patches in an elderly population, as observed in this study. In addition, UV radiation is known to induce immunosuppression, which is known to trigger a rapid development of NMSC.<sup>15</sup> UV radiation is able to induce immunosuppression via a variety of mechanisms including direct immune cell activation and the activation of suppressor immune cells.<sup>16</sup> Both UVA and UVB have distinct effects on immune cell function and it remains possible that seasonal reduction in UV exposure in our device group may have allowed for increased immune surveillance and NMSC clearance. Together, these biological mechanisms provide a possible rationale for the rapid development of NMSC in an elderly population with a history of AKs and a difference in NMSC development following UV avoidance.

Our device was largely accepted by this patient population. We note that the compliance (Figure 4A), as measured by registering UV once in the week, remained above 75% for most of the summer and drops below 50% after November. Given the very low levels of UV in New York in November, a drop in compliance was expected. Figures 4B and 4C show that participants in the intervention group, on average, decreased the number of hours spent outdoors from June to August, and maintained a similar average UV exposure across these months, despite increasing UVR levels. This is what would be observed if they modified their behavior to limit their time outside when UVR levels are increasing.

Furthermore, the two NMSCs reported at disenrollment in the intervention group were diagnosed in participants who stopped using the device a few days after enrollment, providing additional evidence suggesting an impact of the UV dosimeter on NMSC prevention. In Figure 5, we show that the device group participants who had more than one AK at disenrollment experienced a daily average of 0.60 SED across August and September, whereas participants who had 0 or 1 AK experienced a daily average of 0.33 SED across August and September (p=0.0354, Welch's t-test). This suggests that sub-erythral chronic exposure beyond 0.34 SED may contribute to the appearance of AKs. Additional evaluation is needed, as this was not the primary endpoint studied.




**Figure 4.** A. Percentage of participants in the device group who recorded UV exposure in a week. B. Distribution of the mean daily UV exposure per month (one data point per participant per month) in the device group. C. Distribution of the mean daily time spent outdoors per month (one data point per participant per month) in the device group.

When comparing the device group to the control group, we also measured a difference in the change of participants' self-perceived ability to participate in social activities, as measured by the PROMIS short-form questionnaire. The change in t-scores between enrollment and disenrollment differed by 2.1 points ( $p$ -value = 0.01, 95% CI: [3.67, 0.48]) between groups. Notably, the control group's score significantly increased by 1.2 ( $p$ -value = 0.04), while in the device group, the score non-significantly decreased by 0.9 ( $p$ -value = 0.1). This is consistent with a growing awareness of the need to moderate UV exposure in the device group and a possible growing overconfidence after repeat UV counseling in the absence of data in the control group.

We did not observe significant changes, or between-group differences, in self-reported anxiety and depression surveys.

There are several limitations to this study. First, the number of NMSCs is low, which is why we did not present the analysis of SCC and BCC separately. However, their IRRs were also significant ( $p$ -value <  $1e-5$  for SCC and  $p$ -value <  $1.e-5$  for BCC). Second, the study population came from a

single recruiting site in New York, where UVR is lower than in Australia, where similar studies were conducted. Therefore, we would expect to see a larger impact of the device in higher UVR regions. Third, over 85% of our participants completed college, twice the national average; however, the unadjusted incidence rates of NMSC at disenrollment in the device and control groups stratified by education are similar. Fourth, the population was followed for one summer only, leaving the possibility that the device's impact will be short-lived. UV dosimeter use is seasonal, just like sunscreen, and we would expect to see an uptake in usage in the Spring. Fifth, we do not know the UV exposure behavior in the control group. We chose to not conduct a survey of their UV exposure based on their recollection because these surveys have been shown to be unreliable.<sup>17,18</sup> We did not give control participants UV dosimeters without access to real-time data because we wanted a clean comparison to standard-of-care. We were concerned that simply wearing the device could influence control patients' UV behavior. Sixth, we compensated participants in the intervention group (\$40 over six months) if they wore the device at least two days per week, which could have improved their compliance.



**Figure 5.** Distribution of the mean daily UV exposure over August and September as a function of the number of AKs measured at disenrollment among patients in the device group. Using Welch's 2-sample t-test, we found that the group with a low number of AKs had a mean UV exposure of 0.33 SED, and the group with a high number of AKs had a mean UV exposure of 0.60 SED (p-value = 0.0354).

Over the past few years, consumers have learned about their health through the use of sensors in wearable devices (e.g., smartwatches now measure vital signs). This clinical trial is the first to test the use of an accurate wearable UV dosimeter in the context of skin cancer prevention for an elderly population. The clinical benefit measured in this pilot study shows potential for elderly patients and warrants further investigation through larger and longer studies. Similar studies could be conducted in a younger population focusing on sunburn avoidance. Eventually, such accurate sensors could be integrated into current consumer-grade devices (e.g. smartwatches) as a

data-driven, chemical-free sun protection tool. Finally, our trial as well as Chen's on nicotinamide<sup>8</sup> suggest that late-stage events play an important role in skin cancer pathogenesis and further work is needed to delineate these molecular mechanisms.

### **Contributors**

GV was the clinical principal investigator of the study and examined all patients. MB was the clinical study coordinator of the study. JZ, CD, PDK, and ELPD designed the clinical trial. PDK and ELPD digitized the CRFs and prepared the UV exposure data. CD did the statistical analysis. KE provided guidance on the data analysis and manuscript preparation. ELPD wrote the manuscript. All authors reviewed and provided input on the manuscript. All authors had full access to all the data in the study and had final responsibility for the decision to submit for publication.

### **Declaration of interests**

PDK and ELPD are employees and shareholders of Shade, a startup manufacturing wearable UV sensors and the sponsor of this clinical trial. JZ is an advisor and shareholder of Shade.

### **Data Sharing**

Individual participant data will be made available on reasonable requests made to the corresponding author.

## REFERENCES

---

1. Garbe C, Keim U, Gandini S, et al. Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943–2036. *Eur J Cancer*. 2021;152:18-25.
2. Samarasinghe V, Madan V. Nonmelanoma skin cancer. *J Cutan Aesthet Surg*. 2012;5(1):3.
3. Merhi S, Salameh P, Kaplan P, et al. An Ecological Study Indicates the Importance of Ultraviolet A Protection in Sunscreens. *Acta Derm Venereol*. 2021;101(6):adv00480.
4. Matta MK, Zusterzeel R, Pilli NR, et al. Effect of Sunscreen Application Under Maximal Use Conditions on Plasma Concentration of Sunscreen Active Ingredients: A Randomized Clinical Trial. *JAMA*. 2019;321(21):2082-2091.
5. Banerjee S, Hoch EG, Kaplan PD, Dumont ELP. A comparative study of wearable ultraviolet radiometers. In: *2017 IEEE Life Sciences Conference (LSC)*. ; 2017:9-12.
6. Institute NC, National Cancer Institute. Fitzpatrick Classification Scale. *Definitions*. Published online 2020. doi:10.32388/3lujmq
7. Marques E, Chen TM. Actinic Keratosis. In: *StatPearls*. StatPearls Publishing; 2021.
8. Chen AC, Martin AJ, Choy B, et al. A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. *N Engl J Med*. 2015;373(17):1618-1626.
9. Reitsma M, Kendrick P, Anderson J, et al. Reexamining Rates of Decline in Lung Cancer Risk after Smoking Cessation. A Meta-analysis. *Ann Am Thorac Soc*. 2020;17(9):1126-1132.
10. Brash DE, Rudolph JA, Simon JA, et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. *Proc Natl Acad Sci U S A*. 1991;88(22):10124-10128.
11. Boukamp P. Non-melanoma skin cancer: what drives tumor development and progression? *Carcinogenesis*. 2005;26(10):1657-1667.
12. Giglia-Mari G, Sarasin A. TP53 mutations in human skin cancers. *Hum Mutat*. 2003;21(3):217-228.
13. Grandi V, di Gennaro P, Torrigiani S, Basco L, Lastrucci I, Pimpinelli N. Ingenol mebutate-mediated reduction in p53-positive keratinocytes in skin cancerization field directly correlates with clinical response in patients with multiple actinic keratoses. *J Eur Acad Dermatol Venereol*. 2019;33(7):1297-1303.
14. Rebel H, Kram N, Westerman A, Banus S, van Kranen HJ, de Gruijl FR. Relationship between UV-induced mutant p53 patches and skin tumours, analysed by mutation spectra and by induction kinetics in various DNA-repair-deficient mice. *Carcinogenesis*. 2005;26(12):2123-2130.
15. Rangwala S, Tsai KY. Roles of the immune system in skin cancer. *Br J Dermatol*. 2011;165(5):953-965.
16. Molho-Pessach V, Lotem M. Ultraviolet radiation and cutaneous carcinogenesis. *Curr Probl*

*Dermatol.* 2007;35:14-27.

17. Alshurafa N, Jain J, Stump TK, Spring B, Robinson JK. Assessing recall of personal sun exposure by integrating UV dosimeter and self-reported data with a network flow framework. *PLoS One*. 2019;14(12):e0225371.
18. Stump TK, Aspinwall LG, Gray EL, et al. Daily Minutes of Unprotected Sun Exposure (MUSE) Inventory: Measure description and comparisons to UVR sensor and sun protection survey data. *Prev Med Rep*. 2018;11:305-311.

## ABBREVIATIONS

---

AK. Actinic Keratosis

BCC. Basal Cell Carcinoma

CI. Confidence Interval

CRF. Case Report Form

IR. Incidence Rate

IRB. Institutional Review Board

IRR. Incidence Rate Ratio

NCI. National Cancer Institute

NIH. National Institute of Healths

NMSC. Non-Melanoma Skin Cancer

PROMIS. Patient-Reported Outcomes Measurement Information System

SCC. Squamous Cell Carcinoma

SD. Standard Deviation

SED. Standard Erythema Dose

UV. Ultraviolet

UVI. UV Index

UVR. Ultraviolet Radiation